113 related articles for article (PubMed ID: 29427400)
1. Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study.
Huang F; Voelk C; Trampisch M; Rowland L; Schultz A; Sabo JP
Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):84-93. PubMed ID: 29427400
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
Kropeit D; von Richter O; Stobernack HP; Rübsamen-Schaeff H; Zimmermann H
Clin Pharmacol Drug Dev; 2018 Jan; 7(1):9-21. PubMed ID: 28967706
[TBL] [Abstract][Full Text] [Related]
3. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study.
Huang F; Marzin K; Koenen R; Kammerer KP; Strelkowa N; Elgadi M; Quinson AM; Haertter S
J Clin Pharmacol; 2017 Oct; 57(10):1305-1314. PubMed ID: 28513969
[TBL] [Abstract][Full Text] [Related]
4. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers.
Zaltzman JS
Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.
Wu J; Gießmann T; Lang B; Elgadi M; Huang F
J Pharm Pharmacol; 2016 Apr; 68(4):459-66. PubMed ID: 27019158
[TBL] [Abstract][Full Text] [Related]
6. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
Garg V; van Heeswijk R; Lee JE; Alves K; Nadkarni P; Luo X
Hepatology; 2011 Jul; 54(1):20-7. PubMed ID: 21618566
[TBL] [Abstract][Full Text] [Related]
7. Effect of itraconazole on the pharmacokinetics of faldaprevir in healthy subjects.
Huang F; Marzin K; Koenen R; Kammerer KP; Strelkowa N; Elgadi M; Haertter S
Pharmazie; 2021 May; 76(5):189-194. PubMed ID: 33964991
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
[TBL] [Abstract][Full Text] [Related]
9. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
Lam H; Jeffery J; Sitar DS; Aoki FY
Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
[TBL] [Abstract][Full Text] [Related]
10. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects.
Bifano M; Adamczyk R; Hwang C; Kandoussi H; Marion A; Bertz RJ
Clin Drug Investig; 2015 May; 35(5):281-9. PubMed ID: 25896946
[TBL] [Abstract][Full Text] [Related]
11. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants.
Undre N; Dickinson J
BMJ Open; 2017 Apr; 7(4):e012252. PubMed ID: 28377389
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
13. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
El-Hamamsy M; Montasser IF; Mansy AE; Nabet DE; El-Meteini M
J Clin Pharm Ther; 2019 Jun; 44(3):447-453. PubMed ID: 30714175
[TBL] [Abstract][Full Text] [Related]
14. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.
Tremblay S; Nigro V; Weinberg J; Woodle ES; Alloway RR
Am J Transplant; 2017 Feb; 17(2):432-442. PubMed ID: 27340950
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
Wang CH; Ko WJ; Chou NK; Wang SS
Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis.
Rabie R; Mumtaz K; Renner EL
Liver Transpl; 2013 Jan; 19(1):36-48. PubMed ID: 22821730
[TBL] [Abstract][Full Text] [Related]
17. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine.
Taler SJ; Textor SC; Canzanello VJ; Schwartz L; Porayko M; Wiesner RH; Krom RA
Transplantation; 1996 Dec; 62(11):1588-92. PubMed ID: 8970613
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[TBL] [Abstract][Full Text] [Related]
19. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study.
Rathi M; Rajkumar V; Rao N; Sharma A; Kumar S; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Sakhuja V
Transplant Proc; 2015 May; 47(4):1158-61. PubMed ID: 26036543
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.
Feng HP; Caro L; Fandozzi CM; Guo Z; Talaty J; Wolford D; Panebianco D; Iwamoto M; Butterton JR; Yeh WW
J Clin Pharmacol; 2018 May; 58(5):666-673. PubMed ID: 29329497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
